Acrivon Therapeutics, Inc. (ACRV) Company Overview

What does Acrivon Therapeutics do?

Acrivon Therapeutics, Inc. is a clinical-stage oncology biotechnology company listed on the Nasdaq Global Market under the ticker ACRV. It does not sell an approved drug today. Its purpose is to discover and develop cancer therapies while using a proprietary precision-medicine platform to identify the tumors most likely to respond. The official company overview describes a model built around AP3, or Acrivon Predictive Precision Proteomics, and drug-specific tests called OncoSignatures.

The distinction matters. Many precision-oncology strategies begin with a genomic mutation and then search for a drug that targets it. Acrivon starts with a drug, measures how that drug changes signaling pathways in tumor models, and develops a test intended to recognize the same drug-response state in a patient biopsy. Its official science description says AP3 combines high-resolution mass spectrometry with automated tumor-biopsy imaging to measure pathway activity directly rather than relying only on DNA alterations.

Which programs define the pipeline?

The current official pipeline has one late clinical program, one early clinical program, and one preclinical program. ACR-368 is the lead asset and carries the nearest-term registrational opportunity. ACR-2316 is the first internally designed clinical molecule. The CDK11 inhibitor program, also referred to as ACR-6840 in company materials, is intended to demonstrate that the platform can repeatedly generate new assets rather than support only one licensed drug.

How does Acrivon make money if it has no revenue?

Acrivon is financed like a research portfolio rather than an operating drug company. Equity capital is converted into laboratory work, clinical trials, regulatory preparation, companion-diagnostic development, intellectual property, and manufacturing supply. If a program succeeds, future economics could come from direct product sales, a regional or global partnership, sublicensing income, or a strategic transaction. None of those outcomes is assured, and the company has stated in its 2025 Form 10-K that it has never generated revenue and does not expect commercial revenue for years.

Why does the Lilly license matter?

ACR-368, previously known as prexasertib, was licensed from Eli Lilly in January 2021. Acrivon paid a $5.0 million upfront fee and may owe development and commercial milestones of up to $168.0 million, although only $5.0 million is due before a new drug application. The agreement also includes tiered royalties from low single digits to a maximum of 10%. In July 2025, Lilly released its right of first negotiation, giving Acrivon greater control over global partnering and territorial rights while leaving the milestone and royalty burden in place.

What do the latest quarter and 2025 annual results show?

The newest official package is the first-quarter 2026 results, supported by the Form 10-Q for March 31, 2026. The quarter shows a company with substantial near-term liquidity, no product revenue, and spending concentrated on research and development. The key analytical question is not whether current earnings are positive; it is whether the cash runway reaches the next value-changing clinical data.

What changed in Q1 2026?

What does FY2025 add to the picture?

For FY2025, R&D expense was $60.0 million, net loss was $77.9 million, operating cash outflow was $63.7 million, and year-end liquidity was $118.6 million. The annual figures establish the full-year funding burden, while the first-quarter figures show that the company continued to invest at a similar research intensity as it approached major 2026 clinical milestones.

Which clinical programs carry the most value and risk?

Why is ACR-368 the lead valuation driver?

ACR-368 is being studied in a registrational-intent Phase 2b program in endometrial cancer. A January 2026 clinical update reported a confirmed objective response rate of 67% among 12 biomarker-positive serous endometrial-cancer patients. In a broader group with no more than two prior lines of therapy, the confirmed response rate was 52% for 23 serous patients versus 22% for 37 non-serous patients. The contrast supports the biological hypothesis that serous disease may be the more responsive setting, while also showing why a larger all-comer study is necessary.

The next decisive event is the prespecified simultaneous interim analysis of Arm 3, which combines ACR-368 with low-dose gemcitabine, and Arm 4, which evaluates ACR-368 monotherapy in all-comer serous endometrial cancer. Management expects the update in the second half of 2026. The result should influence which arm advances toward completion and therefore affects trial duration, spending, regulatory strategy, and partnering leverage.

What role do ACR-2316 and CDK11 play?

ACR-2316 is strategically important because it was internally designed and is meant to inhibit both WEE1 and PKMYT1. Company data reported 33 patients dosed by late 2025, with tumor shrinkage in 9 of 20 evaluable patients across several tumor types. Those early observations are not proof of efficacy, but they justify continued dose optimization and expansion planning. The CDK11 program is earlier still; its value lies in showing that AP3 can support target selection, molecule design, pharmacodynamic markers, and future OncoSignature development across multiple programs.

Which turning points built Acrivon's current strategy?

Acrivon's history is useful only insofar as it explains today's portfolio and risk structure. The company evolved from a proteomics platform into an integrated drug-and-diagnostic developer, while using a licensed clinical asset to shorten the path to human proof of concept.

1. 2018
   Operations began. The company was organized around the idea that direct measurement of drug-regulated signaling could broaden precision medicine beyond mutation-defined cancers.
2. 2021
   ACR-368 was licensed from Lilly. A clinical-stage molecule gave the young platform a faster route to testing whether AP3-derived patient selection could improve development decisions.
3. 2022
   The initial public offering funded expansion. Public-market capital supported the Phase 2b program, internal discovery, diagnostics, and manufacturing work.
4. 2024
   ACR-2316 entered first-in-human development. The portfolio moved beyond a single licensed molecule and began testing internally designed chemistry in patients.
5. July 2025
   Lilly released its right of first negotiation. Acrivon gained greater freedom to pursue global or regional transactions for ACR-368.
6. December 2025
   Initial ACR-2316 activity was disclosed. Early tumor shrinkage and tolerability observations supported continued dose escalation and 2026 expansion planning.
7. February 2026
   OncoSignature testing moved in-house. A wholly owned CLIA-certified laboratory increased operational control over the diagnostic workflow.

Why did the internal CLIA laboratory change the operating model?

The February 2026 transition is more than a laboratory update. The related Form 8-K states that Acrivon terminated its agreement with Akoya Biosciences without a payment and retained full development and commercialization rights to the ACR-368 OncoSignature. Bringing testing inside the company can improve sample handling, assay learning, turnaround coordination, and regulatory readiness. It also increases fixed responsibilities for quality systems, staffing, validation, and compliance.

What gives Acrivon a competitive advantage?

Acrivon's potential moat is not conventional scale. It is the combination of a drug-specific proteomic data platform, proprietary tests, drug-development know-how, licensed and internally created molecules, clinical datasets, and increasing control over diagnostic operations. These resources are valuable only if they predict response better than standard clinical selection and can be reproduced across programs.

How defensible are AP3 and OncoSignature tests?

The resource-based case is strongest where several assets reinforce each other. AP3 generates drug-response maps; the OncoSignature translates those maps into a biopsy assay; clinical outcomes feed back into assay refinement; and the internal CLIA laboratory can preserve operational learning. The company also reports United States patent protection for an ACR-368 salt form extending through 2037. That date does not guarantee market exclusivity, but it frames the period in which development speed and additional intellectual property matter.

Where is the moat still vulnerable?

A platform is not a moat merely because it is proprietary. Acrivon must show that its tests are analytically reliable, clinically useful, accepted by regulators, practical for trial sites, and economically workable for future payers. It must also demonstrate that the platform can produce more than one successful drug. The most important proof points are therefore the ACR-368 all-comer trial result, reproducible ACR-2316 activity, advancement of CDK11, and the ability of the internal laboratory to support multicenter testing without becoming a bottleneck.

Who competes with Acrivon, and where is its position most exposed?

Acrivon competes at three levels: for biological targets, for patients and trial sites, and for capital. Its 2025 filing identifies rival CHK, WEE1, and PKMYT1 programs, while also warning that larger pharmaceutical companies can run broader trials, manufacture at scale, and commercialize more effectively. The competitive question is not simply whether another molecule hits the same target. It is whether a rival can deliver a better combination of efficacy, safety, convenience, diagnostic simplicity, development speed, price, and reimbursement.

How do industry forces shape the company?

How strong is the balance sheet and capital-allocation profile?

Acrivon's balance sheet is strong enough to fund several scheduled milestones, but it is not self-sustaining. At March 31, 2026, the company reported $34.1 million of cash and cash equivalents, $63.7 million of short-term investments, $99.2 million of current assets, and $11.1 million of current liabilities. It reported no funded debt. After the quarter, an at-the-market equity sale added $7.3 million of net proceeds, which management included in its runway estimate into the third quarter of 2027.

Where did FY2025 R&D spending go?

How should dilution be interpreted?

Equity is the practical financing currency of a pre-revenue biotech company. Common shares outstanding increased after the exercise of pre-funded warrants, and the post-quarter at-the-market sale added cash but also more shares. Dilution is not automatically value destructive if the proceeds fund milestones that materially improve a program's probability of success. It becomes more problematic when capital is raised after delays, weak data, or a falling valuation. Researchers should therefore compare cash runway, milestone timing, share-count growth, and the quality of new evidence together.

Who owns ACRV stock, and why does governance matter?

Acrivon has one class of common stock with one vote per share, so there is no dual-class structure separating economic ownership from voting power. Nevertheless, ownership is concentrated among specialist life-sciences investors and founders. The 2026 proxy statement also describes a classified board, which can provide strategic continuity while making board turnover more gradual.

How concentrated is the disclosed investor base?

Concentrated specialist ownership can be constructive because experienced biotech investors may tolerate long development cycles and understand probability-weighted outcomes. It can also amplify volatility when a large holder changes its view or when the company needs another financing. The classified board structure can add continuity, while the combined CEO and chair roles place more responsibility on independent directors and board committees to oversee capital allocation and clinical risk.

Which KPIs best explain Acrivon's performance?

Traditional revenue-growth and margin screens are not useful for Acrivon yet. The correct dashboard combines clinical evidence, enrollment execution, diagnostic performance, cash consumption, and financing capacity. The company's May 2026 corporate presentation provides the clearest forward milestone map, while filings provide the cash and expense data needed to judge whether the company can reach those milestones.

How should a student interpret the KPI set?

The dashboard reflects a chain of dependencies. A strong response rate is insufficient if the benefit is not durable or the safety profile prevents adequate dosing. Positive biology is insufficient if the assay cannot be deployed reliably across trial sites. A good drug is insufficient if the cash runway ends before pivotal evidence. Conversely, a higher quarterly loss can be rational if it results from faster enrollment, manufacturing readiness, or expansion into a validated cohort. The quality of spending matters more than a simple preference for lower spending.

What opportunities and risks could change Acrivon's outlook?

The largest opportunity is a positive ACR-368 interim analysis that supports a clear registrational path in serous endometrial cancer. Such a result could improve partnering leverage, reduce scientific uncertainty around AP3, and make the internal diagnostic infrastructure more valuable. Additional opportunities include a well-tolerated ACR-2316 expansion dose, evidence of activity in priority lung-cancer populations, advancement of CDK11, and eventual use of the platform in more indications or therapeutic areas.

Which filing-sourced risks are most material?

• Clinical concentration: ACR-368 remains the nearest-term value driver, so disappointing efficacy, durability, safety, or regulatory feedback would affect the entire portfolio narrative.
• Diagnostic dependence: A drug-specific OncoSignature must be analytically valid, operationally reliable, and aligned with drug approval requirements. Failure in the test can delay the drug.
• Financing and dilution: recurring losses and negative cash flow mean additional capital is likely before commercial self-funding, even if the current runway reaches planned milestones.
• Manufacturing reliance: the company depends on contract manufacturers and does not yet have commercial-scale supply arrangements, creating quality, capacity, and timing exposure.
• Competitive timing: rival checkpoint inhibitors or changing standards of care may reduce the addressable population or raise the evidence required for approval and reimbursement.
• Intellectual-property and license burden: patent challenges, third-party claims, or Lilly milestones and royalties could reduce retained economics.
• Key-person and organizational risk: the company depends heavily on its founders and a specialized team; its FY2025 workforce totaled 76 employees, with most personnel focused on research and development.

Why does this business matter for valuation?

A conventional enterprise DCF based on near-term revenue is poorly matched to a pre-revenue biotech. A more useful model values each program separately using addressable patients, treatment duration, net price, launch timing, operating margin, development cost, and probability of technical and regulatory success. Cash is then added, future milestone and royalty obligations are deducted or reflected in margins, and expected dilution is considered. The model is exceptionally sensitive to the probability assigned to ACR-368, the time to approval, and the number of shares outstanding.

What is the key takeaway from Acrivon Therapeutics analysis?

Acrivon is important as a case study in integrated precision oncology. It is attempting to combine drug discovery, proteomic response mapping, patient-selection diagnostics, clinical development, and laboratory execution inside one organization. The model offers a potentially valuable feedback loop, but it also concentrates technical and operational dependencies: the drug, biomarker, manufacturing chain, trial execution, and financing plan all need to work in sequence.